0001209191-15-059967.txt : 20150707 0001209191-15-059967.hdr.sgml : 20150707 20150707171146 ACCESSION NUMBER: 0001209191-15-059967 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150702 FILED AS OF DATE: 20150707 DATE AS OF CHANGE: 20150707 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Chodakewitz Jeffrey CENTRAL INDEX KEY: 0001610876 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 15977145 MAIL ADDRESS: STREET 1: C/O TETRAPHASE PHARMACEUTICALS, INC. STREET 2: 480 ARSENAL ST., SUITE 101 CITY: WATERTOWN STATE: MA ZIP: 02472 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2015-07-02 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001610876 Chodakewitz Jeffrey C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 0 1 0 0 EVP GMDA, CMO Common Stock 2015-07-02 4 M 0 2291 73.51 A 102853 D Common Stock 2015-07-02 4 S 0 394 126.69 D 102459 D Common Stock 2015-07-02 4 S 0 500 128.12 D 101959 D Common Stock 2015-07-02 4 S 0 100 129.54 D 101859 D Common Stock 2015-07-02 4 S 0 1297 130.63 D 100562 D Stock Option (right to buy) 73.51 2015-07-02 4 M 0 2291 0.00 D 2024-01-01 Common Stock 2291 41253 D Transaction made pursuant to Dr. Chodakewitz's company approved trading plan under Rule 10b5-1. Open market sales reported on this line occurred at a weighted average price of $126.69 (range $126.10 to $126.97). Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $128.12 (range $127.81 to $128.47). Open market sales reported on this line occurred at a weighted average price of $130.63 (range $130.58 to $130.68). The option vests in 16 quarterly installments from 01/02/2014. Omar White, Attorney-In-Fact 2015-07-07